Methodological flaws in"diagnostic accuracy of blood biomarkers for Alzheimer's disease and amnestic mild cognitive impairment: A meta-analysis"

Ageing Res Rev. 2023 Jul:88:101938. doi: 10.1016/j.arr.2023.101938. Epub 2023 Apr 23.

Abstract

We read with interest the review by Chen et al. They intended to examine the diagnostic accuracy of blood-based biomarkers for detecting Alzheimer's disease and amnestic mild cognitive impairment. We believe that there were substantial methodological flaws in their meta-analysis. These methodological flaws included no comprehensive literature search details, neglect of the negative result research, no prespecified cut-off values, erroneous data input in their meta-analysis, and the issue of prevalence determined by the included studies. These factors potentially contributed to overestimation of the discriminative accuracy of blood-based biomarkers. Subsequently, the conclusion that blood-based biomarkers are effective tools for detecting Alzheimer's disease is debatable without correction of these methodological flaws and providing robust and trustworthy estimates.

Keywords: Alzheimer disease; Amyloid beta peptides; Biomarkers; Plasma; Tau.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Amyloid beta-Peptides
  • Biomarkers
  • Cognitive Dysfunction* / diagnosis
  • Humans
  • Prevalence
  • tau Proteins

Substances

  • Biomarkers
  • Amyloid beta-Peptides
  • tau Proteins